Aspiriant 13F: New $994K Stake in SPCX

Aspiriant has opened a new position in Space Exploration Technologies Corp. (SPCX) by acquiring 6,590 shares valued at approximately $994,167 in a filing on October 16, 2026. This new buy reflects Aspiriant's interest in the company, which is involved in satellite-based broadband services and reusable rocket design.

What Changed in Aspiriant's SpaceX Position

Aspiriant's new stake consists of 6,590 shares, marking its first investment in SpaceX. This stake is valued at around $994,167. The firm did not report any previous holdings in SpaceX, indicating that this is an initial investment.

Other Institutional Activity in SpaceX

Several institutional investors have shown strong support for SpaceX. For instance, Tema Etfs added 376,475 shares, bringing its total to 563,977 shares worth about $85.1 million. Financial Synergies Wealth Advisors also took a new position with over 4,300 shares. Other notable holders like Alphabet Inc., Valor Management LLC, and FMR, LLC, have maintained significant stakes in the company, indicating continued interest from large investors.

Space Exploration Technologies Corp. Stock Down 4.0%

SpaceX shares recently traded around $143.93, which is below their 50-day moving average of $146.72, by about 1.9%. They also sit below the 200-day average of $145.58, suggesting the stock is in a relative downtrend. Furthermore, the shares are down 36.2% from their 52-week high of $225.64, although they remain above the 52-week low of $104.83 by 37.3%.

Recent Earnings

SpaceX reported trailing twelve-month revenue of $23 billion and an EPS of -$1.10. The company has experienced a revenue growth of 91.9% year-over-year, but it currently faces a net margin of -35.7%. The next earnings report is expected on November 3, 2026.

Insider Buying and Selling at Space Exploration Technologies Corp.

Recently, CEO Elon Musk sold 11,390 shares on April 2, 2026, at an average price of $105.32, totaling approximately $1.2 million. Additionally, President Gwynne E. Shotwell sold 342,170 shares on September 22, 2026, valued at around $52.5 million, both of which were conducted before Aspiriant's recent filing.

Analysts Set New Price Targets

On October 16, 2026, Evercore ISI Group maintained an 'Outperform' rating on SpaceX with a price target of $275. Macquarie also kept its 'Outperform' rating with a target of $250. Overall, analysts suggest a consensus 'buy' rating with a mean price target of $221.26 based on 31 opinions.

About SpaceX

Space Exploration Technologies Corp., commonly known as SpaceX, is based in Starbase, Texas, and provides satellite broadband services along with launching reusable rockets. The company is led by CEO Elon Musk and employs around 21,000 people. Its recent investments and analyst ratings suggest a positive outlook despite the current challenges in profitability.

Bottom Line

Aspiriant's new position in SpaceX reflects growing institutional interest in the company. With analysts bullish on the stock and earnings coming up on November 3, 2026, it will be important to watch how these factors influence the stock's performance moving forward. This filing illustrates holdings as of the reporting period and may not represent the current position of Aspiriant.